Safety of the novel protease-activated receptor-1 antagonist vorapaxar in Japanese patients with a history of ischemic stroke

Journal of Stroke and Cerebrovascular Diseases

Volumn 21, Issue 4, 2012, Pages 318-324

  Shinohara, Yukito ^a   Goto, Shinya ^b   Doi, Masaki ^c   Jensen, Peder ^c  

^a Federation of National Public Service Personnel Mutual Aid Associations   (Japan)

^b TOKAI UNIVERSITY   (Japan)

^c R and D   (Japan)

Author keywords

Atherothrombotic disease; ischemic stroke; PAR 1; protease activated receptor antagonist; protease activated receptor 1; vorapaxar

Indexed keywords

ACETYLSALICYLIC ACID; PLACEBO; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 1 ANTAGONIST; UNCLASSIFIED DRUG; VORAPAXAR;

ADULT; AGED; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; BLOOD CLOT LYSIS; BLOOD PRESSURE; BRAIN INFARCTION; BRAIN ISCHEMIA; CONNECTIVE TISSUE DISEASE; CONSTIPATION; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESOPHAGUS CARCINOMA; FEEDING DISORDER; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEMATOCHEZIA; HEMATOCRIT; HEMATURIA; HEMORRHOID HEMORRHAGE; HUMAN; JAPANESE; LIMB PAIN; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; OCCULT BLOOD; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; STROKE; SUPRAVENTRICULAR PREMATURE BEAT; UPPER ABDOMINAL PAIN;

AGED; BRAIN ISCHEMIA; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; JAPAN; LACTONES; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PYRIDINES; RECEPTOR, PAR-1; RECURRENCE; STROKE; TREATMENT OUTCOME;

EID: 84860134566     PISSN: 10523057     EISSN: 15328511     Source Type: Journal    
DOI: 10.1016/j.jstrokecerebrovasdis.2010.09.005     Document Type: Article

References (21)

1. K. Kimura, K. Minematsu, and S. Kazui Mortality and cause of death after hospital discharge in 10,981 patients with ischemic stroke and transient ischemic attack Cerebrovasc Dis 19 2005 171 178 (Pubitemid 40754335)
2. American Heart Association. Heart Disease and Stroke Statistics. 2009 Update At-A-Glance. Available at: http://www.americanheart.org/downloadable/ heart/123783441267009Heart%20and%20Stroke%20Update.pdf. Accessed on September 28, 2009.
3. J. Vande Griend, and J. Saseen Combination antiplatelet agents for secondary prevention of ischemic stroke Pharmacotherapy 28 2008 1233 1242
4. S. Ishikawa, K. Kayaba, and T. Gotoh Incidence of total stroke, stroke subtypes, and myocardial infarction in the Japanese population: The JMS Cohort Study J Epidemiol 18 2008 144 150
5. G. Davi, and C. Patrono Platelet activation and atherothrombosis N Engl J Med 357 2007 2482 2494
6. D. Varga-Szabo, I. Pleines, and B. Nieswandt Cell adhesion mechanisms in platelets Arterioscler Thromb Vasc Biol 28 2008 403 412
7. T.A. Meadows, and D.L. Bhatt Clinical aspects of platelet inhibitors and thrombus formation Circ Res 100 2007 1261 1275 (Pubitemid 46742917)
8. Antithrombotic Trialists' Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 324 2002 71 86
9. R.L. Sacco, R. Adams, and G. Albers Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: A statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: Co-sponsored by the Council on Cardiovascular Radiology and Intervention: The American Academy of Neurology affirms the value of this guideline Circulation 113 2006 e409 e449 (Pubitemid 43739468)
10. Y. Shinohara Regional differences in incidence and management of stroke - Is there any difference between Western and Japanese guidelines on antiplatelet therapy? Cerebrovasc Dis 21 2006 17 24 (Pubitemid 43254157)
11. Y. Shinohara, and T. Yamaguchi Outline of the Japanese Guidelines for the Management of Stroke 2004 and subsequent revision Int J Stroke 3 2008 55 62 (Pubitemid 351228146)
12. The Joint Committee on Guidelines for the Management of Stroke Japanese guideline for the management of stroke 2009 Kyowa Kikaku, Ltd Tokyo, Japan
13. V.L. Serebruany, S.R. Steinhubl, and P.B. Berger Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials Am J Cardiol 95 2005 1218 1222 (Pubitemid 40616424)
14. S. Chackalamannil, Y. Wang, and W.J. Greenlee Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity J Med Chem 51 2008 3061 3064 (Pubitemid 351821864)
15. S.R. Coughlin Protease-activated receptors in hemostasis, thrombosis and vascular biology J Thromb Haemost 3 2005 1800 1814 (Pubitemid 41716567)
16. L. Reyderman, T. Kosoglou, and C. Kasserra Lack of ethnic differences in the pharmacodynamics (PD) and pharmacokinetics (PK) of SCH 530348, a novel oral antiplatelet agent, in Japanese and Caucasian subjects Clin Pharmacol Ther 85 2009 S21 (abstr PI-41)
17. S. Goto, T. Yamaguchi, and Y. Ikeda Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome J Atheroscler Thromb 17 2010 156 164
18. T. Kosoglou, L. Reyderman, and C. Kasserra Optimizing dose of the novel thrombin receptor antagonist SCH 530348 based on pharmacodynamics and pharmacokinetics in healthy subjects Clin Pharmacol Ther 83 2008 S55 (abstr PII-42)
19. R.C. Becker, D.J. Moliterno, and L.K. Jennings Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: A randomised, double-blind, placebo-controlled phase II study Lancet 373 2009 919 928
20. D.A. Morrow, B.M. Scirica, K.A. Fox on behalf of the TRA 2-P-TIMI 50 Investigators Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: Design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-TIMI 50 trial Am Heart J 158 2009 335 341
21. The TRACER Executive and Steering Committees The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial: Study design and rationale Am Heart J 158 2009 327 334